The European Medicines Agency (EMA) on Tuesday published new draft guidance on the evaluation of anticancer medicines in humans that covers all stages of clinical development.

The guidance, which is available for comment through 15 September, delves into the development of treatments for malignancies, including “drug resistance modifiers or normal tissue protective compounds.”

Back to News